Tamoxifen - the treatment of choice for breast cancer
Author Information
Author(s): M Baum
Primary Institution: University College London Hospital
Hypothesis
Tamoxifen is the most effective treatment for breast cancer, but there may be alternatives.
Conclusion
Tamoxifen significantly reduces the risk of relapse and death in breast cancer patients, especially in post-menopausal women with ER-positive tumors.
Supporting Evidence
- Tamoxifen has a response rate of up to 60% in women with ER-positive tumors.
- Adjuvant tamoxifen therapy can reduce the risk of relapse by 25% and death by 17% over 10 years.
- Tamoxifen treatment may reduce the risk of contralateral breast cancer by about 50%.
- Tamoxifen has a good tolerability profile with serious side effects being rare.
Takeaway
Tamoxifen helps many women with breast cancer live longer and healthier lives, but doctors are looking for even better treatments.
Methodology
The study reviewed various trials and data on tamoxifen's effectiveness in treating breast cancer.
Potential Biases
There may be bias in reporting adverse effects due to more intensive screening of tamoxifen-treated patients.
Limitations
The study does not address the long-term effects of tamoxifen beyond 5 years or the specific impacts on premenopausal women with ER-negative tumors.
Participant Demographics
The study primarily involved post-menopausal women with breast cancer.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website